Search

Bohong Zhang

from Newton, MA
Age ~61
Get Report
Also known as:
Bohang Zhang, Bao L Zhang, Baoling L Zhang, Bohong Shang, Zhang Bohong, Zhang Bao-Ling, Shang Bohong
Phone and address:
155 Washington Ave, Newton, MA 02465
(617) 927-5908
Related to:
Wen Mei ChenWen Li, 67Yu Zhang, 35Hang Chin, 49
Connected to:
Adele Zhang, 32Aiyu Zhang, 58Allen Z Zhang, 58Amanda Zhang, 34Amei Zhang, 56Amy ZhangAmy Q Zhang, 50Angelica C Zhang, 37Aolin Zhang, 35Ava J Zhang, 55

Bohong Zhang Phones & Addresses

  • 155 Washington Ave, West Newton, MA 02465 (617) 927-5908 (617) 969-6583
  • 155 Washington St, Newton, MA 02458
  • 195 Albany St, Cambridge, MA 02139 (617) 927-5908
  • 21 Decatur St #1F, Cambridge, MA 02139 (617) 927-5908
  • 21 Decatur St, Cambridge, MA 02139
  • 249 Dana Ave, Hyde Park, MA 02136
  • Revere, MA
  • 155 Washington Ave, Newton, MA 02465

Professional Records

Medicine Doctors

Bohong Zhang Photo 1

Bohong B Zhang

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
Bohong Zhang
Secretary
DAVID CHENG MUSCAULAR THERAPY GROUP, INC
155 Washington Ave, West Newton, MA 02465
115 Washingotn Ave, West Newton, MA 02465

Publications

Us Patents

Treatment Of Sanfilippo Syndrome Type B

View page
US Patent:
20110318327, Dec 29, 2011
Filed:
Jun 25, 2011
Appl. No.:
13/168969
Inventors:
Michael F. Concino - Bolton MA, US
Pericles Calias - Melrose MA, US
Jing Pan - Boxborough MA, US
Kevin Holmes - Belmont MA, US
Paolo Martini - Boston MA, US
Alla Romashko - Lexington MA, US
Muthuraman Meiyappan - Jamaica Plain MA, US
Bohong Zhang - Newton MA, US
Andrea Iskenderian - Arlington MA, US
Dianna Lundberg - Brentwood NH, US
Angela Norton - Reading MA, US
Bettina Strack-Logue - Somerville MA, US
Yan Huang - Billerica MA, US
Mary Alessandrini - Clinton MA, US
Richard Pfeifer - North Granby CT, US
Assignee:
SHIRE HUMAN GENETIC THERAPIES, INC. - Cambridge MA
International Classification:
A61K 38/47
A61P 43/00
C12N 9/24
US Classification:
424 9461, 435200
Abstract:
Among other things, the present invention provides methods and compositions of treating Sanfilippo syndrome type B (Sanfilippo B) by, e.g., intrathecal (IT) administration of a Naglu protein. A suitable Naglu protein can be a recombinant, gene-activated or natural protein. In some embodiments, a suitable Naglu protein is a recombinant Naglu protein. In some embodiments, a recombinant Naglu protein is a fusion protein containing a Naglu domain and a lysosomal targeting moiety. In some embodiments, the lysosomal targeting domain is an IGF-II moiety.

Treatment Of Sanfilippo Syndrome Type B

View page
US Patent:
20130295077, Nov 7, 2013
Filed:
May 10, 2013
Appl. No.:
13/892076
Inventors:
Pericles Calias - Melrose MA, US
Jing Pan - Boxborough MA, US
Kevin Holmes - Belmont MA, US
Paolo Martini - Boston MA, US
Alla Romashko - Lexington MA, US
Muthuraman Meiyappan - Jamaica Plain MA, US
Bohong Zhang - Newton MA, US
Andrea Iskenderian - Arlington MA, US
Dianna Lundberg - Brentwood NH, US
Angela Norton - Reading MA, US
Bettina Strack-Logue - Somerville MA, US
Huang Yan - Billerica MA, US
Mary Alessandrini - Clinton MA, US
Richard Pfeifer - North Granby CT, US
International Classification:
C12N 9/42
C07K 14/65
US Classification:
424 9461, 435209
Abstract:
Among other things, the present invention provides methods and compositions of treating Sanfilippo syndrome type B (Sanfilippo B) by, e.g., intrathecal (IT) administration of a Naglu protein. A suitable Naglu protein can be a recombinant, gene-activated or natural protein. In some embodiments, a suitable Naglu protein is a recombinant Naglu protein. In some embodiments, a recombinant Naglu protein is a fusion protein containing a Naglu domain and a lysosomal targeting moiety. In some embodiments, the lysosomal targeting domain is an IGF-II moiety.

Recombinant Heme Oxygenase-1 (Ho-1) For The Treatment Of Sickle Cell Disease

View page
US Patent:
20230018417, Jan 19, 2023
Filed:
Jul 24, 2020
Appl. No.:
17/623503
Inventors:
- Lexington MA, US
- Pittsburgh PA, US
Joseph Sypek - Lexington MA, US
Bohong Zhang - Lexington MA, US
Xiuxia Sun - Lexington MA, US
Clark Q. Pan - Lexington MA, US
Daniel Minard Lajole - Lexington MA, US
Chuan Shen - Lexington MA, US
International Classification:
A61K 38/44
A61P 7/06
C12N 15/62
C12N 9/02
Abstract:
The present invention provides, among other things, methods and compositions for making and using recombinant heme oxygenase for treating sickle cell disease. In some embodiments, recombinant heme oxygenase proteins are truncation variants, or Fc fusion proteins with increased half-life and/or reduced aggregation.

Affinity Purification Of Glycoside-Cleaving Enzymes

View page
US Patent:
20210040465, Feb 11, 2021
Filed:
Mar 5, 2019
Appl. No.:
16/978417
Inventors:
- Lexington MA, US
Bohong Zhang - Lexington MA, US
Jun Hu - Lexington MA, US
Muthuraman Meiyappan - Lexington MA, US
Thomas Miller - Lexington MA, US
Paul McLean - Lexington MA, US
Clark Pan - Lexington MA, US
Assignee:
SHIRE HUMAN GENETIC THERAPIES, INC. - Lexington MA
International Classification:
C12N 9/40
Abstract:
The invention relates to an affinity resin functionalized with small molecule inhibitors of glycoside-cleaving enzymes, e.g., α-galactosidase A (α-Gal A), glucocerebrosidase (GCB), β-galactosidase, and acid alpha-glucosidase (GAA), and a method for purifying glycoside-cleaving enzymes produced in a cell line using the small molecule inhibitor-functionalized affinity resin.

Mannose-6-Phosphate Bearing Peptides Fused To Lysosomal Enzymes

View page
US Patent:
20200376095, Dec 3, 2020
Filed:
Jun 18, 2020
Appl. No.:
16/904943
Inventors:
- Lexington MA, US
Bettina STRACK-LOGUE - Lexington MA, US
Muthuraman MEIYAPPAN - Lexington MA, US
Angela W. NORTON - Lexington MA, US
Bohong ZHANG - Lexington MA, US
Andrea ISKENDERIAN - Lexington MA, US
Lieh Yoon LOW - Lexington MA, US
Dianna LUNDBERG - Lexington MA, US
Alla ROMASHKO - Lexington MA, US
Hicham NAIMY - Lexington MA, US
International Classification:
A61K 38/47
A61K 38/43
A61K 38/17
A61K 38/20
A61K 38/30
C07K 14/47
C07K 14/54
C07K 14/65
C12N 9/12
Abstract:
A targeted therapeutic including a lysosomal enzyme and a lysosomal targeting moiety that is a peptide containing at least one N-linked glycosylation site. Methods of producing the targeted therapeutic may include nucleotide acids encoding the same and host cells co-expressing GNPT. Pharmaceutical compositions comprising the targeted therapeutic and methods of using the same to treat a lysosomal storage disease.

Treatment Of Sanfilippo Syndrome Type B

View page
US Patent:
20180085438, Mar 29, 2018
Filed:
Sep 26, 2017
Appl. No.:
15/715748
Inventors:
- Lexington MA, US
Pericles Calias - Melrose MA, US
Jing Pan - Boxborough MA, US
Kevin Holmes - Belmont MA, US
Paolo Martini - Boston MA, US
Alla Romashko - Lexington MA, US
Muthuraman Meiyappan - Jamaica Plain MA, US
Bohong Zhang - Newton MA, US
Andrea Iskenderian - Arlington MA, US
Dianna Lundberg - Brentwood NH, US
Angela Norton - Reading MA, US
Bettina Strack-Logue - Somerville MA, US
Huang Yan - Billerica MA, US
Mary Alessandrini - Clinton MA, US
Richard Pfeifer - North Granby CT, US
International Classification:
A61K 38/47
A61K 9/00
A61K 9/19
A61K 38/46
C12N 9/24
A61K 35/76
A61K 35/761
C07K 14/65
C12N 9/42
A61K 9/08
A61K 47/02
A61K 47/26
Abstract:
Among other things, the present invention provides methods and compositions of treating Sanfilippo syndrome type B (Sanfilippo B) by, e.g., intrathecal (IT) administration of a Naglu protein. A suitable Naglu protein can be a recombinant, gene-activated or natural protein. In some embodiments, a suitable Naglu protein is a recombinant Naglu protein. In some embodiments, a recombinant Naglu protein is a fusion protein containing a Naglu domain and a lysosomal targeting moiety. In some embodiments, the lysosomal targeting domain is an IGF-II moiety.

Lysosomal Targeting And Uses Thereof

View page
US Patent:
20180009904, Jan 11, 2018
Filed:
Nov 20, 2015
Appl. No.:
15/529355
Inventors:
Bohong ZHANG - Lexington MA, US
Michael F. CONCINO - Bolton MA, US
International Classification:
C07K 16/40
C12N 9/26
C12N 9/24
A61K 38/00
Abstract:
The invention provides compositions and methods for effective lysosomal targeting mediated by PCSK9. In particular, the compositions and methods provided by the invention may be used to treat lysosomal storage diseases such as Pompe Disease and Sanfilippo Syndrome Type B, and they may be used for targeting lysosomal enzymes to the various muscles of the human body.

Lysosomal Targeting And Uses Thereof

View page
US Patent:
20170246263, Aug 31, 2017
Filed:
Aug 11, 2015
Appl. No.:
15/503227
Inventors:
- Lexington MA, US
Bettina STRACK-LOGUE - Lexington MA, US
Muthuraman MEIYAPPAN - Lexington MA, US
Angela W. NORTON - Lexington MA, US
Bohong ZHANG - Lexington MA, US
Andrea ISKENDERIAN - Lexington MA, US
Jianwen FENG - Lexington MA, US
Kevin HOLMES - Lexington MA, US
Pan Jing - Lexington MA, US
International Classification:
A61K 38/47
C12N 9/24
C07K 14/705
Abstract:
The invention provides compositions and methods for effective lysosomal targeting mediated by SORT1. In particular, the compositions and methods provided by the invention may be used to treat lysosomal storage diseases such as Sanfilippo syndrome type B.
Control profile
Bohong Zhang from Newton, MA, age ~61 Get Report